Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.
Chimeric Therapeutics Limited has announced the appointment of Miles Prince as a director, effective July 1, 2025. The initial director’s interest notice reveals that Prince currently holds no securities or interests in the company, indicating a fresh start for his involvement. This appointment may influence the company’s strategic direction and strengthen its leadership team as it continues to develop its CAR-T therapies.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies, aiming to address unmet medical needs in oncology.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.07M
Learn more about CHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
- Ford Mustang Cobra Jet Fastest Electric Car on the Planet, Ford Stock (NYSE:F) Notches Up
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test